摘要
目的探讨西妥昔单抗治疗老年k-RAS野生型转移性结直肠癌(mCRC)的效果,为治疗该病症提供方法。方法选取解放军联勤保障部队第九〇四医院2015年10月至2019年10月收治的68例老年k-RAS野生型mCRC患者为研究对象,按照随机数字表法将其分为研究组和对照组,各34例。对照组采用常规化疗,研究组在对照组的基础上另给予西妥昔单抗。持续治疗12周后评价治疗效果。比较两组近期抗肿瘤效果、治疗前后肿瘤标志物变化情况,并统计两组安全性。结果研究组临床控制率高于对照组,差异有统计学意义(P<0.05)。治疗前两组血清癌胚抗原(CEA)、糖类抗原(CA)199比较,差异无统计学意义(P>0.05);治疗后两组CEA、CA199较治疗前均降低,且研究组低于对照组,差异均有统计学意义(均P<0.05)。两组痤疮样皮疹、骨髓抑制、肝功能损伤、消化道反应发生率比较,差异均无统计学意义(P>0.05)。结论对老年k-RAS野生型mCRC患者实施西妥昔单抗治疗可明显增强抗肿瘤疗效,降低瘤标志物水平,且患者耐受性良好。
Objective To explore the efficacy of Cetuximab in the treatment of elderly k-RAS wild-type metastatic colorectal cancer(mCRC),and to provide a method for the treatment of this disease.Methods A total of 68 elderly patients with k-RAS wild-type mCRC admitted to NO.904 Hospital of the Joint Logistics Support Force of the Liberation Army from October 2015 to October 2019 were selected as the research subjects.According to random number table method,they were divided into study group and control group,with 34 cases in each group.The control group received conventional chemotherapy,and the research group received Cetuximab in addition to the control group.The therapeutic effect was evaluated after 12 weeks of continuous treatment.The recent anti-tumor effect and the changes of tumor markers before and after treatment were compared between the two groups,and the safety of the two groups was statistically analyzed.Results The clinical control rate in the study group was higher than that in the control group,and the difference was statistically significant(P<0.05).Before treatment,there were no significant differences in serum carcinoembryonic antigen(CEA)and carbohydrate antigen(CA)199 between the two groups(P>0.05).After treatment,CEA and CA199 in both groups were lower than those before treatment,and those in the study group were lower than those in the control group,with statistical significance(all P<0.05).There was no statistical significance in the incidence of acne-like rash,myelosuppression,liver function injury and digestive tract reaction between the two groups(P>0.05).Conclusion Cetuximab treatment for elderly patients with k-RAS wild-type mCRC can significantly enhance the anti-tumor efficacy,reduce the level of tumor markers and the patient are well tolerated.
作者
谭琴
任顺安
周仁贵
TAN Qin;REN Shun’an;ZHOU Rengui(Department of Hematology and Oncology,No.904 Hospital of the Joint Logistics Support Force of the Liberation Army,Jiangsu Province,Wuxi214000,China;Department of Respiratory Medicine,No.904 Hospital of the Joint Logistics Support Force of the Liberation Army,Jiangsu Province,Wuxi214000,China)
出处
《中国医药导报》
2021年第23期100-103,共4页
China Medical Herald
基金
江苏省自然科学基金项目(BK20170137)。
